ClinicalTrials.gg
TerminatedNCT00792740CDUpdated Jul 19, 2023Results posted

Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease

A Phase 1/2 interventional study of ITF2357 and Placebo in Crohn's Disease, sponsored by Italfarmaco. Terminated at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-19.

Sponsored by Italfarmaco · Phase 1/2, Interventional, and Treatment

Why this study was terminated
As no safety warnings were detected, Interim analysis from the first 40 patients recommends to stop the trial for futility

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Oct 2007, registered Nov 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.

Enrollment
146th of 175
51 · median 211
Started
2007
with 3 others
Phase 1/2
3 of 194
none open now
Registered
34th of 194
by date

Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 146th largest by enrollment of the 175 interventional ones that give a count, is one of 4 that started in 2007, is one of 3 in phase 1/2, and was the 34th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Crohn Disease with a site in Belgium, or all of them as a file.
02

Study summary

Objectives:

The primary objective of the study was to determine the ability of ITF2357, administered orally at the dose of 50 mg b.i.d. for 8 consecutive weeks, to induce complete healing of mucosal ulcerations of ileum and/or colon, assessed by endoscopy, in patients with endoscopic and clinical evidence of active moderate-to-severe Crohn's disease not controlled by conventional therapies.

The secondary objectives of the study were:

  • to evaluate the effect of ITF2357 on endoscopic disease activity assessed using both the Crohn's Disease Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score of Crohn's Disease (SES-CD);
  • to evaluate the effect of ITF2357 on clinical disease activity, assessed using the Crohn's Disease Activity Index (CDAI);
  • to assess the safety and tolerability of ITF2357; to assess the pharmacokinetic profile of ITF2357.
Read the detailed description

The study was conducted according to a randomized, double-blind placebo-controlled, parallel group design in up to 25 clinical sites in Europe.

Eligible patients were randomly assigned to two parallel treatment groups (1:1 randomization ratio) receiving either ITF2357, as hard gelatine capsule for oral administration, at the dose of 50 mg b.i.d. (total daily dose of 100 mg), or matching placebo capsules.

Treatment was administered on an outpatient basis for 8 consecutive weeks, followed by a 4-week follow-up.

During screening, in the 8-week treatment period and in the 4-week follow-up period, patients attended scheduled visits, with physical and laboratory assessments, in order to monitor disease evolution and safety and tolerability of ITF2357.

The study was planned to be conducted in up to 80 patients of both genders, with established diagnosis of CD, who presented with ulcerations greater than aphthous ulcers in at least one of the five bowel segments investigated endoscopically, from the ileum to the rectum, with endoscopic and clinical evidence of moderate-to-severe active disease, not controlled by on-going treatment with conventional therapies such as 5-aminosalicylates, steroids or immunosuppressants.

The present study has been designed in order to assessed wether short-term (8 weeks) treatment with oral ITF2357 can induce disease improvement in a substantial proportion of patients.

Its aim to evaluate whether a short term treatment with ITF2357 for 8 weeks, at the selected dose of 50 mg b.i.d., is able to induce healing of mucosal lesions, evaluated endoscopically, in patients with endoscopic and clinical evidence of moderate-to-severe active Crohn's disease, not controlled by ongoing treatment with conventional therapies such as 5-aminosalicylates, steroids or immunosuppressants, was not addressed and the study was prematurely interrupted according to IDSMC (Independent Data and Safety Monitoring Committee) decision, based on the results of the interim analysis, which did not demonstrate any benefit of ITF2357 over placebo in the primary variable rate of patients achieving complete healing at week 8.

There was also no evidence of benefits in patients treated with ITF2357 compared to placebo in the secondary efficacy endpoints (full remission rate, remission rate, CDEIS endoscopic response, changes from baseline of CDEIS score and SES-CD score, changes from baseline of CDAI score, CDAI remission rate, and CDAI response rate).

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: > 18 years
  • Diagnosis of CD, re-established by endoscopy and/or X-ray and/or surgery in the last 36 months
  • CD in active phase since at least 2 weeks before screening
  • CDAI between 220 and 450
  • CDEIS > 8
  • Ulcerations greater than aphthous ulcers in at least 1 of the bowel segments from ileum to rectum
  • If any on-going treatment with (prednisone, prednisolone or budesonide), it must be at a dose equivalent to or less than 30 mg/day prednisone, or 9 mg of budesonide, and in use for at least one month and at a stable dose for at least two weeks before patient enrolment
  • If any on-going treatment with (azathioprine, 6-mercaptopurine, methotrexate), it must be in use for at least 3 months before patient enrolment
  • If any on-going treatment with 5-aminosalicylates, it must be in place for at least 4 weeks before patient enrolment, at a dose > 2 g
  • Females of with negative pregnancy tests
  • Signed written to participate in this trial.

Exclusion criteria

Exclusion Criteria:

  • Treatment in the 2 months with anti-TNF-alfa antibodies and in the previous 3 months with cytokines inhibitors or experimental drugs
  • Primary failure to previous treatment with anti-TNF-alfa antibodies-
  • Current bowel obstruction or any condition that may predispose to its development (e.g. unresolved intestinal stricture, adhesions or any other condition that would place the patient at risk for developing overt bowel obstruction) or intestinal perforation or significant GI hemorrhage
  • Expected surgery for the duration of the study
  • Any ostomy or extensive bowel resection
  • Positive serological anti- and anti- testing and positive testing for active replication, e.g. HBV-DNA or HBsAg or HBeAg (to be performed at screening)
  • Other on-going clinical relevant viral infections (e.g. herpes zoster, Epstein-Barr, CMV), systemic fungal infections or history of recurrent serious bacterial infections
  • Signs and symptoms of severe, progressive or uncontrolled renal, hepatic, haematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease
  • Any previous evidence, irrespective of its severity, of coronary disease, cardiac rhythm abnormalities or congestive heart failure
  • > 450 msec at pre-treatment evaluation
  • Serum magnesium and potassium below the LLN at pre-treatment evaluation
  • counts below 200 x 10\^9/L at pre-treatment evaluation
  • Any previous evidence, irrespective of its severity, of renal function impairment
  • Unavoidable concomitant treatment with any drug known for potential risk of causing Torsades de Pointes
  • Presence of a transplanted organ
  • History of cancer with less than 5 years documentation of a disease-free state
  • History of tuberculosis
  • Severe lactose intolerance
  • Pregnant or nursing women
  • Female of without using a safe measure
  • Participation in a clinical trial within 30 days prior to initiation of study treatment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Oral matching placebo capsules, administered bid.

    Other: Placebo

  • Experimental
    ITF2357

    Oral ITF2357 50 mg bid

    Drug: ITF2357

Interventions

  • ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.

    Also known as: Givinostat

  • OtherPlacebo

    Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)

06

What researchers measure

Primary outcomes

  1. Number of Patients Achieving Complete Healing of Mucosal Ulcerations of Ileum and/or Colon

    The outcome is assessed by endoscopy, in patients with endoscopic and clinical evidence of active moderate-to-severe Crohn's disease not controlled by conventional therapies. The outcome measure defines the rate of patients achieving complete healing in ITT population, i.e disappearance of mucosal ulceration, obtained with ITF2357 treatment.

    Time frame: At week 8

Secondary outcomes

  1. Number of Patients Achieving Full Endoscopic Remission ( Based on CDEIS Score)

    CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was defined 'fully endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than three points CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon. The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. The higher the score, the worse is patient's situation.

    Time frame: At Week 8

  2. Number of Patients Achieving Endoscopic Remission (Based on CDEIS Score)

    CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was defined 'endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than six points. CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon ). The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. The higher the score, the worse is patient's situation. Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. A patient was defined 'endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than six points.

    Time frame: At week 8

  3. Number of Patients Achieving Endoscopic Response (Based on CDEIS Score)

    CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was considered in 'endoscopic response' whether the change in CDEIS score at week 8 versus baseline was equal or greater than 4.5 points. CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon ). The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. The higher the score, the worse is patient's situation Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. A patient was considered in 'endoscopic response' whether the change in CDEIS score at week 8 versus baseline was equal or greater than 4.5 points.

    Time frame: At week 8

  4. The Mean Changes of Crohn's Disease Endoscopic Index of Severity (CDEIS) From Baseline to Week 8

    CDEIS is an index to determ the endoscopic severity of Crohn's disease. Its score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). These 4 parameters are: Deep ulcerations (12 if present, 0 if absent = total 1); Superficial ulcerations (6 if present, 0 if absent = total 2); Surface involved by disease (mm/10 on VAS = = total 3); Surface involved by ulcerations (mm/10 on VAS = total 4). Sum of Totals 1+2+3+4 =Total A Number of segments visualized in part or entirely (from 1 to 5)= n Total A/n =Total B if ulcerated stenosis in any segment, add 3 =Total C If non-ulcerated stenosis in any segment, add 3= Total D Total B+C+D=CDEIS grand score (min=0; max=NA) Decoding score \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. The higher the score, the worse is patient's status.

    Time frame: From Baseline to week 8

  5. The Mean Changes of Simple Endoscopic Score for Crohn Disease (SES-CD) From Baseline to Week 8

    SES-CD is another index to determ the endoscopic severity of Crohn's disease. Its score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). These 4 parameters are: ulcers? 0: no; 1: aphthous (0.1-0.5 cm); 2: large (0.5-2 cm); 3: very large (\>2 cm); Surface involved by inflammation 0: 0% 1: \<50% 2: 50-75% 3: \>75% Surface involved by ulcerations 0: 0% 1. \<10% 2. 10-30% 3. \>30% Stenosis? 0: No 1. Single, can be passed 2. Multiple, can be passed 3. Cannot be passed The scores for each individual segment are added together as a sum score (min=0; max=60) The higher the score, the worse the outcome. Decoding score 0 - 2 remission 3 - 6 mild endoscopic activity 7 - 15 moderate endoscopic activity \> 15 severe endoscopic activity

    Time frame: From Baseline to week 8

  6. The Mean Changes of CDAI Score From Baseline to Week 4-8-follow up

    CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points

    Time frame: Weeks 4 and 8, and follow-up at 1 month

  7. Number of Patients Achieving Remission (Based on CDAI Score)

    "Remission" is defined as the disappearance of signs and symptoms of the disease. CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points

    Time frame: Weeks 4 and 8, and follow-up at 1 month

  8. Number of Patients Achieving Response (Based on CDAI Score)

    "Response" is defined as the reaction to a stimulus or to a treatment, especially in a favorable way. CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation. A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points

    Time frame: Weeks 4 and 8, and follow-up at 1 month

  9. Number of Patients With at Least One Related Adverse Event to Study Treatment

    Treatment-related adverse events are adverse events (AE) which occurs during an interventional study and which are surely related to study treatment dosing.

    Time frame: At Pre-Treatment period (Week 0); At treatment period (Week 1, Week 2, Week 4, week 6, Week 8); At Follow-up period (1month)

  10. Plasma Levels of ITF2357 Before Morning Dose of ITF2357

    Individual plasma levels of ITF2357 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.

    Time frame: Pre-dose, week 2, week 4, week 6

  11. Plasma Levels of Metabolite ITF2374 Before Morning Dose of ITF2357.

    Individual plasma levels of metabolite ITF2374 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.

    Time frame: Pre-dose, week 2, week 4, week 6

  12. Plasma Levels of Metabolite ITF2375 Before Morning Dose of ITF2357.

    Individual plasma levels of Metabolite ITF2375 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.

    Time frame: Pre dose, week 2, week 4, week 6.

07

Results

Posted Jul 19, 2023

Participant flow

Fifty-one (51) subjects were enrolled in the study, as planned, and 37 of them completed the study as per protocol.

Participant flow — Overall Study
MilestonePlaceboITF2357
Started2625
Completed1918
Not completed77
Withdrew: Disease worsening32
Withdrew: Personal reason10
Withdrew: Adverse event13
Withdrew: Patient's withdrawal of consent01
Withdrew: Termination of the trial by the sponsor20
Withdrew: Other reasons01

Outcome measures

PrimaryNumber of Patients Achieving Complete Healing of Mucosal Ulcerations of Ileum and/or Colon

The outcome is assessed by endoscopy, in patients with endoscopic and clinical evidence of active moderate-to-severe Crohn's disease not controlled by conventional therapies. The outcome measure defines the rate of patients achieving complete healing in ITT population, i.e disappearance of mucosal ulceration, obtained with ITF2357 treatment.

Time frame:
At week 8
Reported as:
Count of participants · Participants
Number of Patients Achieving Complete Healing of Mucosal Ulcerations of Ileum and/or Colon
ParticipantsPlaceboITF2357
Number of Patients Achieving Complete Healing of Mucosal Ulcerations of Ileum and/or Colon01
SecondaryNumber of Patients Achieving Full Endoscopic Remission ( Based on CDEIS Score)

CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was defined 'fully endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than three points CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon. The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. The higher the score, the worse is patient's situation.

Time frame:
At Week 8
Reported as:
Count of participants · Participants
Number of Patients Achieving Full Endoscopic Remission ( Based on CDEIS Score)
ParticipantsPlaceboITF2357
Number of Patients Achieving Full Endoscopic Remission ( Based on CDEIS Score)21
SecondaryNumber of Patients Achieving Endoscopic Remission (Based on CDEIS Score)

CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was defined 'endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than six points. CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon ). The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. The higher the score, the worse is patient's situation. Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. A patient was defined 'endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than six points.

Time frame:
At week 8
Reported as:
Count of participants · Participants
Number of Patients Achieving Endoscopic Remission (Based on CDEIS Score)
ParticipantsPlaceboITF2357
Number of Patients Achieving Endoscopic Remission (Based on CDEIS Score)35
SecondaryNumber of Patients Achieving Endoscopic Response (Based on CDEIS Score)

CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was considered in 'endoscopic response' whether the change in CDEIS score at week 8 versus baseline was equal or greater than 4.5 points. CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon ). The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. The higher the score, the worse is patient's situation Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. A patient was considered in 'endoscopic response' whether the change in CDEIS score at week 8 versus baseline was equal or greater than 4.5 points.

Time frame:
At week 8
Reported as:
Count of participants · Participants
Number of Patients Achieving Endoscopic Response (Based on CDEIS Score)
ParticipantsPlaceboITF2357
Number of Patients Achieving Endoscopic Response (Based on CDEIS Score)67
SecondaryThe Mean Changes of Crohn's Disease Endoscopic Index of Severity (CDEIS) From Baseline to Week 8

CDEIS is an index to determ the endoscopic severity of Crohn's disease. Its score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). These 4 parameters are: Deep ulcerations (12 if present, 0 if absent = total 1); Superficial ulcerations (6 if present, 0 if absent = total 2); Surface involved by disease (mm/10 on VAS = = total 3); Surface involved by ulcerations (mm/10 on VAS = total 4). Sum of Totals 1+2+3+4 =Total A Number of segments visualized in part or entirely (from 1 to 5)= n Total A/n =Total B if ulcerated stenosis in any segment, add 3 =Total C If non-ulcerated stenosis in any segment, add 3= Total D Total B+C+D=CDEIS grand score (min=0; max=NA) Decoding score \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. The higher the score, the worse is patient's status.

Time frame:
From Baseline to week 8
Reported as:
Mean · score on a scale
The Mean Changes of Crohn's Disease Endoscopic Index of Severity (CDEIS) From Baseline to Week 8
score on a scalePlaceboITF2357
The Mean Changes of Crohn's Disease Endoscopic Index of Severity (CDEIS) From Baseline to Week 8-2.5 ± 5.6-2.4 ± 4.2
SecondaryThe Mean Changes of Simple Endoscopic Score for Crohn Disease (SES-CD) From Baseline to Week 8

SES-CD is another index to determ the endoscopic severity of Crohn's disease. Its score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). These 4 parameters are: ulcers? 0: no; 1: aphthous (0.1-0.5 cm); 2: large (0.5-2 cm); 3: very large (\>2 cm); Surface involved by inflammation 0: 0% 1: \<50% 2: 50-75% 3: \>75% Surface involved by ulcerations 0: 0% 1. \<10% 2. 10-30% 3. \>30% Stenosis? 0: No 1. Single, can be passed 2. Multiple, can be passed 3. Cannot be passed The scores for each individual segment are added together as a sum score (min=0; max=60) The higher the score, the worse the outcome. Decoding score 0 - 2 remission 3 - 6 mild endoscopic activity 7 - 15 moderate endoscopic activity \> 15 severe endoscopic activity

Time frame:
From Baseline to week 8
Reported as:
Mean · score on a scale
The Mean Changes of Simple Endoscopic Score for Crohn Disease (SES-CD) From Baseline to Week 8
score on a scalePlaceboITF2357
The Mean Changes of Simple Endoscopic Score for Crohn Disease (SES-CD) From Baseline to Week 8-2.6 ± 4.5-2.0 ± 4.0
SecondaryThe Mean Changes of CDAI Score From Baseline to Week 4-8-follow up

CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points

Time frame:
Weeks 4 and 8, and follow-up at 1 month
Reported as:
Mean · score on a scale
The Mean Changes of CDAI Score From Baseline to Week 4-8-follow up
score on a scalePlaceboITF2357
At week 4-85.3 ± 95.9-32.7 ± 84.5
At week 8-119 ± 96.5-54.7 ± 94.3
At follow-up 1 month-106 ± 91.6-83.8 ± 82.0
SecondaryNumber of Patients Achieving Remission (Based on CDAI Score)

"Remission" is defined as the disappearance of signs and symptoms of the disease. CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points

Time frame:
Weeks 4 and 8, and follow-up at 1 month
Reported as:
Count of participants · Participants
Number of Patients Achieving Remission (Based on CDAI Score)
ParticipantsPlaceboITF2357
At week 4104
At week 8147
At follow-up after one month119
SecondaryNumber of Patients Achieving Response (Based on CDAI Score)

"Response" is defined as the reaction to a stimulus or to a treatment, especially in a favorable way. CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation. A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points

Time frame:
Weeks 4 and 8, and follow-up at 1 month
Reported as:
Count of participants · Participants
Number of Patients Achieving Response (Based on CDAI Score)
ParticipantsPlaceboITF2357
At week 4116
At week 8148
At follow up, after one month1411
SecondaryNumber of Patients With at Least One Related Adverse Event to Study Treatment

Treatment-related adverse events are adverse events (AE) which occurs during an interventional study and which are surely related to study treatment dosing.

Time frame:
At Pre-Treatment period (Week 0); At treatment period (Week 1, Week 2, Week 4, week 6, Week 8); At Follow-up period (1month)
Reported as:
Count of participants · Participants
Number of Patients With at Least One Related Adverse Event to Study Treatment
ParticipantsPlaceboITF2357
Number of Patients With at Least One Related Adverse Event to Study Treatment1312
SecondaryPlasma Levels of ITF2357 Before Morning Dose of ITF2357

Individual plasma levels of ITF2357 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.

Time frame:
Pre-dose, week 2, week 4, week 6
Reported as:
Mean · ng/mL
Plasma Levels of ITF2357 Before Morning Dose of ITF2357
ng/mLITF2357
Pre-dose0.00 ± 0.00
Week 216.87 ± 6.09
Week 416.97 ± 11.54
Week 614.50 ± 6.78
SecondaryPlasma Levels of Metabolite ITF2374 Before Morning Dose of ITF2357.

Individual plasma levels of metabolite ITF2374 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.

Time frame:
Pre-dose, week 2, week 4, week 6
Reported as:
Mean · ng/mL
Plasma Levels of Metabolite ITF2374 Before Morning Dose of ITF2357.
ng/mLITF2357
Pre-dose0.00 ± 0.00
Week 215.09 ± 6.92
Week 412.93 ± 7.36
Week 613.24 ± 8.16
SecondaryPlasma Levels of Metabolite ITF2375 Before Morning Dose of ITF2357.

Individual plasma levels of Metabolite ITF2375 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.

Time frame:
Pre dose, week 2, week 4, week 6.
Reported as:
Mean · ng/mL
Plasma Levels of Metabolite ITF2375 Before Morning Dose of ITF2357.
ng/mLITF2357
pre-dose0.00 ± 0.00
week 2121.23 ± 88.83
week 4112.80 ± 109.74
week 6101.36 ± 76.32

Adverse events

Collected over Adverse event data were collected from Week 0 up to week 8 and during follow up period (which lasts for one month). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/26 (0%)2/26 (7.7%)17/26 (65.4%)
ITF23570/25 (0%)3/25 (12%)20/25 (80%)
Most frequent serious events
Most frequent serious events
EventPlaceboITF2357
Crohn's DiseaseGastrointestinal disorders1/263/25
Back PainMusculoskeletal and connective tissue disorders1/260/25
Most frequent other events
Showing 10 of 67
Most frequent other events
EventPlaceboITF2357
VomitingGastrointestinal disorders1/266/25
Abdominal painGastrointestinal disorders4/265/25
Crohn's diseaseGastrointestinal disorders3/264/25
Abdominal pain upperGastrointestinal disorders1/263/25
DyspepsiaGastrointestinal disorders0/263/25
NauseaGastrointestinal disorders1/263/25
PyrexiaGeneral disorders0/263/25
DehydrationMetabolism and nutrition disorders0/263/25
HypokalaemiaMetabolism and nutrition disorders0/263/25
ArthralgiaMusculoskeletal and connective tissue disorders2/263/25

Baseline characteristics

ITT: All randomized patients who received at least one treatment with study medication

Age, Categorical
Age, Categorical(Participants)PlaceboITF2357Total
<=18 years000
Between 18 and 65 years262450
>=65 years011
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboITF2357Total
Female161430
Male101121
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboITF2357Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White262551
More than one race000
Unknown or Not Reported000
08

Study locations

10 sites
  • AZ Sint Lucas Gastro-enterologie
    Assebroek, 8310, Belgium
  • Imelda Hospital Gastro-enterology dept.
    Bonheiden, 2820, Belgium
  • CHU Saint-Pierre Médecine Interne
    Bruxelles, 1000, Belgium
  • UZ Gent Gastro-enterologie 1K12IE
    Gent, 9000, Belgium
  • AZ Groeninge (St-Niklaas) Gastro-enterologie
    Kortrijk, 8500, Belgium
  • University Hospital Gasthuisber
    Leuven, 3000, Belgium
  • Divisione di Gatroenterologia Istituto Clinico Humanitas IRCCS in. Gastroenterology
    Rozzano, 20089, Italy
  • Vrije Universiteit (VU) Medisch Centrum Afdeling M.D.L.ziekten
    Amsterdam, 1007 MB, Netherlands
  • Academisch Medisch Centrum (AMC) Afdeling M.D.L. ziekten
    Amsterdam, 1100 DD, Netherlands
  • Leids Universitair Medisch Centrum (LUMC) Afdeling M.D.L. ziekten
    Leiden, 2300 RC, Netherlands
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2007 to primary completion in Dec 2008, 14 months.

Results were first posted in Jul 2023, 14 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2008
First posted
Nov 18, 2008
StartActual
Oct 22, 2007
Primary completionActual
Dec 2008
CompletionActual
Mar 11, 2009
Results first posted
Jul 19, 2023
Last update
Jul 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00792740
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Nov 18, 2008
Start date
Oct 22, 2007
Primary completion
Dec 2008
Completion
Mar 11, 2009
Results posted
Jul 19, 2023
Last update
Jul 19, 2023

Study contacts

Paul Rutgeerts, MD
study chair · University Hospital Gasthuisberg, Leuven, Belgium

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion